Medical directoryActive ingredient
Retatrutide
An investigational triple agonist. It is NOT licensed or marketed: any offer to sell it to the public is illegal and dangerous. AiON does not prescribe it.
Content reviewed by Dr. David Céspedes
Medical guides
Orforglipron (Foundayo): the first GLP-1 pill with no restrictions, and why it isn't available in Spain
ReadRetatrutide: what its phase 3 trial found, and why you can't get hold of it
ReadCagriSema: what it is, what the REDEFINE trials found and why it disappointed
ReadGLP-1: what it is, how it works and why it is transforming obesity treatment
Read
Keep reading
This entry is for information. Your case requires an individual medical assessment.